AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read$TWST

WERNER ROBERT F. sold $213K of TWST

WERNER ROBERT F. (Chief Accounting Officer) sold 1,523 shares of Twist Bioscience Corp (TWST) at an average of $140.02 ($139.07–$140.77, $0.21M total) across 2 trades over 2026-08-21 to 2026-08-24.

Original reporting
SEC EDGAR · WERNER ROBERT F.
Published Aug 25, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming financing or compensation events not disclosed.

Relevance 4/10Novelty 4/10Timing: post-filing

Background

Form 4 filings disclose insider transactions; traders monitor for signals.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Chief Accounting Officer sold 1,523 shares for $213K, reducing his stake to 44,637 shares.

Expected impact

Potential slight downward pressure in short term.

Evidence & confidence

Sale amount is under $1M and represents a small percentage of total holdings; market reaction likely limited.

Market effects

Sector

Minimal impact on biotech sector; insider activity is routine.

Regional

No regional effect.

Global

Limited to Twist Bioscience investors.

Counterpoint

What could challenge this read

Sale could be unrelated to company outlook; insider may need liquidity.

Key entities

  • Company
    Twist Bioscience Corp

    Biotech company listed on NASDAQ.

  • Insider
    Werner Robert F.

    Chief Accounting Officer of Twist Bioscience.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

SEP 17
$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

timothysykes.com2 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min
SEP 17
$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

stockstotrade.com3 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

timothysykes.com2 min